TABLE 2.

ORR

Parameter	Efficacy Population (N = 50)
	RANO-HGGa	RANO-LGGb	Combined HGG/LGGc
ORR, No. (%) [95% CI]	10 (20.0) [10.0 to 33.7]	13 (26.0) [14.6 to 40.3]	15 (30.0) [17.9 to 44.7]
CR	1 (2.0)	0	1 (2.0)
PR	9 (18.0)	6 (12.0)	9 (18.0)
MR	NA	7 (14.0)	5 (10.0)
SD	10 (20.0)	8 (16.0)	7 (14.0)
NE	8 (16.0)d	11 (22.0)e	11 (22.0)
PD	18 (36.0)	14 (28.0)	13 (26.0)
NA	4 (8.0)f	4 (8.0)f	4 (8.0)f
DCR, No. (%) [95% CI]	20 (40.0) [26.4 to 54.8]	21 (42.0) [28.2 to 56.8]	22 (44.0) [30.0 to 58.7]

Abbreviations: BICR, blind independent central review; CR, complete response; DCR, disease control rate (CR + PR + SD); HGG, high-grade glioma; LGG, low-grade glioma; MR, minor response; MRI, magnetic resonance imaging; NA, not applicable; NE, not evaluable; ORR, overall response rate; PD, progressive disease; PR, partial response; RANO, response assessment in neuro-oncology; SD, stable disease.

^a Integrated RANO-HGG criteria assessment by dual-reader BICR.

^b Integrated RANO-LGG criteria assessment by dual-reader BICR.

^c Incorporates the best response by RANO-HGG or RANO-LGG criteria for each patient.

^d Five overall radiographic SD accompanied by increase in corticosteroids; three overall radiographic PD accompanied by decrease in corticosteroids.

^e Eight overall radiographic SD accompanied by increase in corticosteroids; three overall radiographic PD accompanied by decrease in corticosteroids.

^f Three patients did not have on-treatment monotherapy MRIs available for BICR; one patient censored before first on-treatment MRI.